巴曲酶治疗早期急性缺血性脑卒中疗效分析

The efficacy of Batroxobin on early acute ischemic stroke

目的:探讨巴曲酶治疗早期急性缺血性脑卒中的疗效。方法:选取2014年1月至2014年12月收治的早期急性缺血性脑卒中患者50例,随机分为观察组和对照组(各25例),其中对照组采用常规治疗方法,观察组在常规治疗的基础上第1、第3、第5天给予巴曲酶10、5、5 BU加入0.9%氯化钠溶液中静滴。观察2组患者治疗前、治疗后14 d静脉血纤维蛋白原含量变化,治疗前、治疗后14 d及90 d神经功能缺损评分(NIHSS)及治疗效果。结果:观察组纤维蛋白原含量及NIHSS评分均明显低于对照组(P<0.05);治愈率及总有效率均高于对照组(P<0.01)。结论:巴曲酶能降低早期急性缺血性脑卒中患者纤维蛋白原含量,改善预后,提高生活质量。

Objective: To investigate the efficacy of Batroxobin on early acute ischemic stroke. Methods:Selected 50 patients with early acute ischemic stroke from January 2014 to December 2014, were randomly divided into observation group and control group. The control group was given with conventional treatment, and the observation group based on conventional therapy with batroxobin administering treatment. Fibrinogen levels,functional neurological deficit (NIHSS) score and treatment were observed. Results: Fibrinogen content and NIHSS score in observation group were significantly lower than those in the control group (P<0.05); the cure rate and the total effective rate between two groups was statistically significant (P<0.01). Conclusion: Batroxobin can reduce the fibrinogen, improve the prognosis and quality of life for early acute ischemic stroke.